PRESS RELEASE published on 02/14/2025 at 22:10, 1 year 8 months ago GENFIT Announces the Amendment of the Final Terms of the Dual Proposal to the 2025 OCEANEs Holders GENFIT announces amendment of final terms of dual proposal to 2025 OCEANEs holders, seeking consent for repurchase at EUR 32.75 per bond or a consent fee of EUR 0.90 per bond still outstanding Repurchase Amendment GENFIT Consent Fee 2025 OCEANEs
BRIEF published on 02/10/2025 at 07:35, 1 year 8 months ago GENFIT Proposes Terms for 2025 OCEANEs Bondholders Royalty Financing GENFIT Bond Repurchase Financial Terms 2025 OCEANEs
BRIEF published on 02/10/2025 at 07:35, 1 year 8 months ago GENFIT propose des modalités aux porteurs d'OCEANEs 2025 Rachat D'obligations GENFIT Conditions Financières OCEANE 2025 Financement Par Redevances
PRESS RELEASE published on 02/10/2025 at 07:30, 1 year 8 months ago GENFIT Announces Final Terms for Dual Proposal to the 2025 OCEANEs Holders GENFIT announces final terms for dual proposal to the 2025 OCEANEs holders, offering to repurchase bonds at EUR 32.00 or pay a consent fee of EUR 0.60 per bond. Proposals subject to bondholders' approval and closing of royalty financing Repurchase Royalty Financing GENFIT Consent Fee 2025 OCEANEs
PRESS RELEASE published on 02/10/2025 at 07:30, 1 year 8 months ago GENFIT annonce les termes définitifs de sa double proposition aux porteurs d’OCEANEs 2025 GENFIT annonce les termes de sa double proposition aux porteurs d'OCEANEs 2025, incluant le rachat des obligations ou un paiement financier, liés au royalty financing avec HCRx. Modalités d'approbation et mise en œuvre Rachat Royalty Financing GENFIT OCEANEs 2025 Contrepartie Financière
BRIEF published on 02/06/2025 at 22:15, 1 year 9 months ago GENFIT dévoile ses futurs essais cliniques et attentes pour 2025 Biopharmaceutique Essais Cliniques 2025 GENFIT ACLF
BRIEF published on 02/06/2025 at 22:15, 1 year 9 months ago GENFIT unveils its future clinical trials and expectations for 2025 Clinical Trials Biopharmaceutical 2025 GENFIT ACLF
PRESS RELEASE published on 02/06/2025 at 22:10, 1 year 9 months ago GENFIT présente le design de ses prochains essais cliniques et rappelle les grandes étapes de développement et données cliniques attendues en 2025 GENFIT présente le design de ses prochains essais cliniques pour son portefeuille ACLF et rappelle les données cliniques attendues en 2025. Le Directeur Général annonce quatre séries de données cliniques attendues d'ici fin 2025 Développement Essais Cliniques GENFIT ACLF Données Cliniques
PRESS RELEASE published on 02/06/2025 at 22:10, 1 year 9 months ago GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025 GENFIT outlines anticipated new clinical trial initiations, development milestones, and data readouts in 2025, focusing on Acute on-Chronic Liver Failure (ACLF) pipeline Clinical Trials Biopharmaceutical 2025 GENFIT ACLF Pipeline
BRIEF published on 01/30/2025 at 08:45, 1 year 9 months ago GENFIT Announces €185 Million Royalty Financing Agreement Biopharmaceutical Royalty Financing GENFIT Debt Resolution ACLF Development
Published on 11/06/2026 at 22:15, 21 hours 9 minutes ago Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders
Published on 11/06/2026 at 13:00, 1 day 6 hours ago Alaska Energy Metals Achieves High Extraction Rates of Metals from Hydromet Testing, Nikolai Nickel Project, Alaska
Published on 11/06/2026 at 12:30, 1 day 6 hours ago Relevant Gold Receives Expanded Drilling Approvals for the Lewiston Project in Wyoming
Published on 11/06/2026 at 12:30, 1 day 6 hours ago Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
Published on 11/07/2026 at 13:35, 5 hours 49 minutes ago Eurobattery Minerals board member and CEO remanded in custody in Sweden
Published on 11/06/2026 at 20:15, 23 hours 9 minutes ago African Medicines Agency Marks First Year of Operations with New Platforms to Strengthen Regulation and Support Manufacturing
Published on 11/06/2026 at 20:15, 23 hours 9 minutes ago L’Agence africaine des médicaments marque sa première année d’activité avec le lancement de nouvelles plateformes pour renforcer la réglementation et soutenir la fabrication
Published on 11/06/2026 at 19:15, 1 day ago EQS-Adhoc: ABO Energy GmbH & Co. KGaA suspends the interest payment on the bond 2024/2029 due on 8 November 2026.
Published on 11/06/2026 at 19:00, 1 day ago Finexity AG: FINEXITY issues 2026/2030 bond with a minimum of 7.00% p.a. – either conventionally in a securities account or as a crypto security in a wallet
Published on 11/06/2026 at 19:06, 1 day ago ALTAREIT : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES OCTOBRE 2026
Published on 11/06/2026 at 19:04, 1 day ago ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 11/06/2026 at 19:01, 1 day ago ALTAREA : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES OCTOBRE 2026
Published on 11/06/2026 at 19:00, 1 day ago ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL